TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Lisinopril in Children and Adolescents With a Kidney Transplant

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Kidney transplant recipient~2. Age 2-17 years, inclusive, at the time of first study dose~3. Estimated GFR (eGFR) ≥30 ml/min/1.73m2, with stable allograft function as indicated by \<20% change in serum creatinine in the previous 30 days~4. Stable immunosuppressive regimen, as indicated by \<10% change in dosage (in mg/kg) in these medications, within the 14 days prior to enrollment~5. Systolic BP \>90th percentile for age, gender, and height, necessitating initiation or addition of an antihypertensive medication~6. For females of child-bearing potential, a negative serum pregnancy test prior to initial dosing and agreement to practice appropriate contraceptive measures, including abstinence, from the time of the initial pregnancy testing through the remainder of the study (30 days after last administration of investigational agents).~Exclusion Criteria:~1. History of anaphylaxis attributable to lisinopril or other angiotensin-converting enzyme inhibitor (ACEI) agents (e.g.,enalapril, ramipril, quinapril)~2. History of anaphylaxis attributable to iohexol or an iodine hypersensitivity~3. Use of an angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker, or renin antagonist within 30 days prior to enrollment~4. Stage 2 hypertension defined as the \>99th percentile for age, height and gender + 5 mm Hg~5. Blood Potassium value \> 6.0 milliequivalent / liter (mEq/L) (as determined at the screening visit)~6. Previous participation in this study~7. Physician concern that the participant may not adhere to the study protocol, based on prior behavior~8. Current plasmapheresis treatment~9. History of angioedema~10. Pregnancy

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose: Lisinopril (Type: EXPERIMENTAL): Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day
- Medium Dose: Lisinopril (Type: EXPERIMENTAL): Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day
- High Dose: Lisinopril (Type: EXPERIMENTAL): Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BIFI-OBESE: Clinical Trial in Paediatric Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. both sexes~2. between 6 and 18 years of age~3. obese, according to the IOTF criteria (Cole TJ et al., 2000)~4. pubertal stage ≥ 2 according to the Tanner stage (Tanner et al., 1961)~5. HOMA-IR \> 2,5 or insulin \> 15 µU/ml~Exclusion Criteria:~1. Adverse reactions to the product or component of the product (allergies...)~2. Genetic obesity (Prader Willi syndrome, Down syndrome), Metabolic obesity (Laurence-biedl syndrome...), endocrinological obesity (Cushinch syndrome, hypotiroidism)~3. Chronic diseases, hepatic or gastroenterological diseases~4. Medical treatment for chronic diseases~5. Probiotic or prebiotic therapies and antibiotic treatment

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Active group Bifidobacterium breve BR03 and B632 (Type: ACTIVE_COMPARATOR): This arm will receive a supplementation of probiotic containing Bifidobacterium breve B632 and Bifidobacterium breve BR03, 15 gtt/die (3x108 CFU/die) once a day.
- Placebo group (Type: PLACEBO_COMPARATOR): This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* history of blepharitis and meet qualifying criteria for an acute exacerbation of blepharitis in both eyes at Screening and Baseline/Day 1 Visits~* have a qualifying best-corrected visual acuity~Exclusion Criteria:~* abnormality of the eyelids or lashes (other than blepharitis), or previous eyelid surgery~* IOP \> 21 mmHg at Screening or Baseline/Day 1 Visits~* use of steroids in the past 30 days or retinoids in the past 12 months~* uncontrolled systemic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NCX 4251 QD (Type: EXPERIMENTAL): NCX 4251 Ophthalmic Suspension, 0.1% once daily for 14 days
- Placebo QD (Type: PLACEBO_COMPARATOR): Placebo once daily for 14 days
- NCX 4251 BID (Type: EXPERIMENTAL): NCX 4251 Ophthalmic Suspension, 0.1% twice daily for 14 days
- Placebo BID (Type: PLACEBO_COMPARATOR): Placebo twice daily for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~• Diagnosed with Low High Density Lipoprotein Cholesterol (HDL-C) or hypercholesterolemia, after diet lead-in/washout of lipid therapies~Exclusion Criteria:~* History of coronary heart disease, or hardening of the arteries, or heart does not pump sufficiently well~* Hypertension or high blood pressure that is not under control or your study physician does not consider the electrical activity of heart (Electrocardiogram \[ECG\]) to be compatible with participation in the study~* History of a bad skin rash, a prior rash due to a drug or a history of chronic skin disorder (such as psoriasis or eczema)~* Intolerance to certain lipid modifying drugs (including statins and Cholesteryl Ester Transfer Protein (CETP) inhibitors)~* Not willing to stop taking prescription or over the counter drugs you use to control fats in your blood (like fish oil, niacin or statin) or pills to decrease your weight, including herbs~* Not willing to follow the diet (low-fat) that the study physician will recommend~* Have disease of liver, kidneys, muscles or other organs of body, a serious infection or cancer, or abnormal laboratory tests that study physician does not consider compatible with participation in the study~* Breastfeeding woman or a woman who can still become pregnant, but are not willing to use a valid birth control measure to prevent pregnancies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 30 milligram (mg) LY2484595 monotherapy (Type: EXPERIMENTAL): None
- 100 mg LY2484595 monotherapy (Type: EXPERIMENTAL): None
- 500 mg LY2484595 monotherapy (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- 20 mg Atorvastatin monotherapy (Type: ACTIVE_COMPARATOR): None
- 100 mg LY2484595 + 20 mg Atorvastatin (Type: EXPERIMENTAL): None
- 40 mg Simvastatin monotherapy (Type: ACTIVE_COMPARATOR): None
- 100 mg LY2484595 + 40 mg Simvastatin (Type: EXPERIMENTAL): None
- 10 mg Rosuvastatin monotherapy (Type: ACTIVE_COMPARATOR): None
- 100 mg LY2484595 + 10 mg Rosuvastatin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Heart Rate Regularization in Patients With Permanent Atrial Fibrillation Post Marketing Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has signed informed consent form~* Patient with permanent atrial fibrillation, standard indication for VVI(R) pacing, and at least 1 episode of rate irregularity in the last month~* New York Heart Association (NYHA) Class I, II, III~* Patient is able to comply with follow-up times and will comply with the protocol~* \> 18 years of age~Exclusion Criteria:~* Paroxysmal atrial fibrillation~* NYHA Class IV~* Left ventricular ejection fraction (LVEF) \< 35~* Patients with unstable angina~* Patients who have experienced an acute myocardial infarction or received coronary artery revascularization (CABG), or coronary angioplasty (PTCA) within 3 months prior to enrolment~* Patient candidate for cardiac surgery, or coronary angioplasty (PTCA)~* Patients who experienced a cardiovascular accident (CVA) or transient ischemic attack (TIA) with permanent disability~* Life expectancy \< 12 months due to other medical conditions~* Pregnancy~* The patient is enrolled in any concurrent (drug and/or device) study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1. VRS ON (Type: EXPERIMENTAL): Patients with permanent atrial fibrillation implanted with VVI(R) pacemaker Vitatron model C20 SSIR or T20 SSIR were randomized to Function Ventricular Rate Stabilization (VRS) ON or OFF.~This arm (1) is randomized to Function Ventricular Rate Stabilization ON.
- 2. VRS OFF (Type: NO_INTERVENTION): Patients with permanent atrial fibrillation implanted with VVI(R) pacemaker Vitatron model C20 SSIR or T20 SSIR were randomized to Function Ventricular Rate Stabilization (VRS)ON or OFF.~This arm (2) is randomized to Function Ventricular Rate Stabilization OFF.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who weigh ≥8 kilogram (kg) without shoes and wearing light clothing at the Screening Visit~* Subjects with confirmed diagnosis of CF at the Screening Visit~* Subjects who are homozygous for the F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutation~Exclusion Criteria:~* Any clinically significant laboratory abnormalities at the Screening Visit that would interfere with the study assessments or pose an undue risk for the subject~* An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 28 days before Day 1~* A standard 12-lead ECG demonstrating QTc \>450 millisecond (msec) at the Screening Visit.~* History of solid organ or hematological transplantation.~* Ongoing or prior participation in an investigational drug study (including studies investigating LUM and/or IVA) within 30 days of the Screening Visit.~* History of cataract/lens opacity or evidence of cataract/lens opacity determined to be clinically significant by a licensed ophthalmologist during the ophthalmologic examination at the Screening Visit

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Lumacaftor/Ivacaftor (LUM/IVA) (Type: EXPERIMENTAL): Part A (\<14 kg): Participants weighing less than (\<) 14 kilograms (kg) at screening received LUM 100 milligram (mg)/IVA 125 mg fixed-dose combination every 12 hours for 15 days in Part A.~Part A (\>=14 kg): Participants weighing greater than or equal to (\>=) 14 kg at screening received LUM 150 mg/IVA 188 mg fixed-dose combination every 12 hours for 15 days in Part A.~Part B (\<14 kg): Participants weighing \<14 kg at screening received LUM 100 mg/IVA 125 mg fixed-dose combination every 12 hours for 24 weeks in Part B.~Part B (\>=14 kg): Participants weighing \>=14 kg at screening received LUM 150 mg/IVA 188 mg fixed-dose combination every 12 hours for 24 weeks in Part B.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety and Efficacy Study of Peginterferon Beta-1a

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must have completed the study treatment and visit schedule through Week 96 in Study 105MS301 (NCT00906399).~Key Exclusion Criteria:~* Subjects exceeding more than 6 weeks since completion of the Week 96 visit of Study 105MS301 (NCT00906399).~* Subjects with any clinically significant laboratory abnormalities, malignancies, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease~* Pregnant or nursing women.~NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- peginterferon beta-1a Q4W (Type: EXPERIMENTAL): 125 µg peginterferon beta-1a administered by subcutaneous (SC) injection every 4 weeks (Q4W) for at least 2 years and up to 4 years.
- peginterferon beta-1a Q2W (Type: EXPERIMENTAL): 125 μg peginterferon beta-1a administered by SC injection every 2 weeks (Q2W) for at least 2 years and up to 4 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-45. Individuals over the age of 45 will not be included as we are examining the effects of menstrual cycle and ovarian hormones.~* Daily smokers who smoke at least 10 cigarettes per day for at least past 6 months.~* Post menarche and pre menopausal~* Regular menstrual cycle between 25 and 35 days~* At least three months post delivery and breast feeding~* Desire to quit smoking and willingness to participate in a research study.~* Women with a history of depression (but not current MDE) and current PMDD will be included. Excluding women with these diagnoses would have a major impact on feasibility, but because both disorders might impact treatment outcome, individuals will be stratified across randomization groups.~Exclusion Criteria:~* Any unstable major axis I psychiatric disorder in the past month~* Current substance use disorders other than nicotine and caffeine use, in the past 30 days.~* Any medication that may interfere with psychophysiological monitoring~* Unstable medical or serious medical condition in the past 6 months~* Hypersensitivity to varenicline or TNP~* Use of other tobacco products~* Use of other medications with smoking cessation efficacy within 30 days prior to enrollment~* BMI less than 15 since this could alter hormone levels that affect menstrual phase~* Pregnancy~* Breast feeding~* Status post hysterectomy~* Birth control or HRT medication that would effect the menstrual cycle. Currently available oral contraceptives contain either a combination of a synthetic estrogen and synthetic progestin, or a progestin alone. Estrogen and/or progestin inhibit ovulation and alter cervical mucus and the endometrium by suppressing the production of follicle-stimulating hormone and the luteinizing hormone surge (Bucci \& Carson, 1997)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Varenicline (Type: EXPERIMENTAL): Participant randomized to receive active varenicline and placebo transdermal nicotine patch.
- Transdermal Nicotine Patch (Type: ACTIVE_COMPARATOR): Participant randomized to receive active transdermal nicotine patch and placebo varenicline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Effect of Different Treatment Course With Inhaled Corticosteroids in Eosinophilic Bronchitis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who have a history of cough as sole or main symptom lasting more than 3 weeks.~2. Patients whose chest x-ray outcome was normal or without any active focus.~3. Patients who were diagnosed with the result of sputum eosinophil percentage (Eos%) over 2.5%, and the negative result in bronchial provocation test by methacholine inhalation challenge.~4. Patients who was aged from 18 years old (≥ 18 years old ) to 75 years old (≤ 75 years old).~Exclusion Criteria:~1. Patients who is a smoker or ex-smoker and has smoked within the previous year or has a cumulative smoking history \>10 pack-years or equivalence.~2. Patients with concomitance of GERC (gastroesophageal reflux-related chronic cough), chronic bronchitis , bronchiectasis, bronchial tuberculosis, ACEI induced cough, bronchogenic carcinoma, psychologic cough, pulmonary fibrosis, bronchus foreign body, microlithiasis, tracheobroncheopathia osteochondroplastica, mediastinal tumor, left ventricular dysfunction.~3. Female subjects who are pregnant, breast-feeding or risk of becoming pregnant during the study.~4. Subjects who are known or suspected to be hypersensitive to any component of the study medication or relief medications.~5. Subjects who have received any therapy in the previous 4 weeks, e.g.corticosteroids ,antihistamines, leukotriene receptor antagonist in previous 4 weeks~6. Subjects who are diagnosed with past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease, endocrine disease or pulmonary disease. e.g.nasal-sinus infection, lower respiratory tract infection, chronic bronchitis, emphysema, bronchiectasis, cystic fibrosis or bronchopulmonary dysplasia.~7. Subjects who demonstrate significant abnormality on biochemistry, hematology, ECG.~   -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Inhaled budesonide for 4 weeks (Type: ACTIVE_COMPARATOR): inhaled Budesonide 100µg , 2puff Q12h for 4 weeks
- Inhaled budesonide for 8 weeks (Type: ACTIVE_COMPARATOR): inhaled Budesonide 100µg , 2puff Q12h for 8 weeks
- Inhaled budesonide for 16 weeks (Type: ACTIVE_COMPARATOR): inhaled Budesonide 100µg , 2puff Q12h for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of chronic hepatitis C.~* Liver biopsy performed within 2 years of Day 0 or during screening.~* Infected with hepatitis C virus genotype 1.~* Interferon alfa treatment naïve (ie, have never been treated with an interferon product).~* Subjects are eligible to enter the study if they (or their partners) are not pregnant or nursing, are sterile, or of non childbearing potential, or are willing to practice abstinence or use appropriate birth control methods during the study and for 7 months after the last dose of ribavirin.~* Have compensated liver disease.~Key Exclusion Criteria:~* Decompensated liver disease including those subjects with a past history or presence of ascites, bleeding varices or hepatic encephalopathy.~* History of moderate, severe or uncontrolled psychiatric disease, especially depression, including a history of hospitalization or prior suicidal attempt.~* Positive for human immunodeficiency virus (HIV-1) or hepatitis B surface antigen (HBsAG).~* Clinical diagnosis of other causes of chronic liver disease including but not limited to hepatitis B, autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver disease, hemochromatosis, Wilson's Disease, or alpha 1-antitrypsin deficiency.~* A history of immunologically mediated disease (eg, rheumatoid arthritis, inflammatory bowel disease, moderate/severe psoriasis, sarcoidosis, systemic lupus erythematosus).~* Active seizure disorder within the last 2 years.~* Organ transplant other than cornea and hair transplant.~* Clinically significant hemoglobinopathy (eg, thalassemia, sickle cell anemia).~* Cancer within the last 5 years(with the exception of adequately treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix).~* Drug or alcohol addiction within the last 6 months. Subjects in a supervised methadone treatment program may be enrolled in the study.~* Received any experimental agent within 28 days prior to Day 0.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 180 mcg PEG-IFNx2a every 1 week (48 doses) + Ribavirin 1000 or 1200 mg/day
- 2 (Type: EXPERIMENTAL): 900 mcg alb-IFN every 2 weeks (24 doses)+ Ribavirin 1000 or 1200 mg/day
- 3 (Type: EXPERIMENTAL): 1200 mcg alb-IFN every 2 weeks (24 doses)+ Ribavirin 1000 or 1200 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete